Wednesday, July 8, 2026

Patent intelligence · US

US 10774083

Heterocyclic amide compound

granted A61KA61K31/437A61K31/4439A61K31/444
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 14
Applicant portfolio 1,436
Patent details — US 10774083
Jurisdiction
US
Status
granted
Grant date
Sep 15, 2020
Expiration
Sep 10, 2040
Claims
5
CPC classes
A61K, A61K31/437, A61K31/4439, A61K31/444
View on Google Patents ↗

Quick answer

US 10774083 (Heterocyclic amide compound) is held by Takeda Pharmaceutical Company Limited. Status: granted. Granted Sep 15, 2020. Expires Sep 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
5
CPC classes
A61K, A61K31/437, A61K31/4439, A61K31/444, A61K31/501, A61K31/506

More from Takeda Pharmaceutical Company Limited

Related pharmaceutical patents in our USPTO index.

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Expires Sep 25, 2045

    granted
  2. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  3. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  5. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Expires Sep 4, 2045

    granted
  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted
  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 10774083?

US 10774083 (Heterocyclic amide compound) is held by Takeda Pharmaceutical Company Limited. Status: granted. Granted Sep 15, 2020. Expires Sep 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10774083?

Takeda Pharmaceutical Company Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.

When does US 10774083 expire?

Our index shows an expiration date of Sep 10, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.